2011
DOI: 10.1016/j.atherosclerosis.2011.07.113
|View full text |Cite
|
Sign up to set email alerts
|

Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: Findings from in vitro and ex vivo studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
73
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 91 publications
(77 citation statements)
references
References 26 publications
4
73
0
Order By: Relevance
“…Aerobic exercise has been shown to statins and niacin increase HDL cholesterol efflux capacity 14,17) . In contrast, studies including ours reported that treatment with pioglitazone, a peroxisome proliferator-activated receptor (PPAR ) agonist, resulted in a significant increases in HDL cholesterol efflux capacity in patients with metabolic syndrome and/or DM 14,18) . It was shown that PPAR agonist increased ATP-binding cassette A1 (ABC A1) in liver X receptor (LXR)-dependent manner, which resulted in enhanced cholesterol efflux capacity 18) .…”
Section: Introductionmentioning
confidence: 61%
See 3 more Smart Citations
“…Aerobic exercise has been shown to statins and niacin increase HDL cholesterol efflux capacity 14,17) . In contrast, studies including ours reported that treatment with pioglitazone, a peroxisome proliferator-activated receptor (PPAR ) agonist, resulted in a significant increases in HDL cholesterol efflux capacity in patients with metabolic syndrome and/or DM 14,18) . It was shown that PPAR agonist increased ATP-binding cassette A1 (ABC A1) in liver X receptor (LXR)-dependent manner, which resulted in enhanced cholesterol efflux capacity 18) .…”
Section: Introductionmentioning
confidence: 61%
“…In contrast, studies including ours reported that treatment with pioglitazone, a peroxisome proliferator-activated receptor (PPAR ) agonist, resulted in a significant increases in HDL cholesterol efflux capacity in patients with metabolic syndrome and/or DM 14,18) . It was shown that PPAR agonist increased ATP-binding cassette A1 (ABC A1) in liver X receptor (LXR)-dependent manner, which resulted in enhanced cholesterol efflux capacity 18) . In addition, our group reported that addition of telmisartan, a PPAR -activating angiotensin type 1 receptor blocker to cell cultures also increased ABC A1 and LXR in macrophage gene expression and enhanced cholesterol efflux capacity from THP-1 macrophages 19).…”
Section: Introductionmentioning
confidence: 61%
See 2 more Smart Citations
“…Briefly, THP-1 cells (Riken Cell Bank, Tsukuba, Japan) were maintained in RPMI 1640 (NikkenBio,Kyoto,Japan)containing10%fetalbovine serum. THP-1 cells were differentiated into macrophages with 320 nmol/l phorbol 12-myristate13-acetatefor72hours.Forthemeasurementofcholesterol efflux, the cells were cultured in a 24-well plate at a densityof1.0×10 6 cells/well.Themacrophageswere washed twice with phosphate buffered saline (PBS) and labeled via incubation in the presence of [ 3 H]-cholesterol(PerkinElmer,Boston,USA;finalconcentration 0.33 μCi/ml) in medium containing 0.2% bovine serum albumin (BSA) for 24 hours.The cells were washed twice with PBS containing 0.2% BSA andincubatedfor24hoursat37 ℃ inmediumcontaining0.2%BSAinthepresenceof0.5%serum(v/v) obtained from the study subjects as a cholesterol acceptor [25][26][27] .Followingincubation,thecultureswere centrifuged to remove cell debris, and the medium wasremovedtodeterminethelevelofradioactivity.At theendofthechaseperiod,themacrophagesweredissolved in a 3:2 (v/v) mixture of hexane/isopropanol, and the level of radioactivity per aliquot was measured.Thepercentageofcholesteroleffluxwascalculated by dividing the media-derived radioactivity by serum cholesterol efflux capacity was 32.6±5.7% in themenintheNGTgroup,31.6±6.0%inthemen intheIGTgroupand31.3±7.2%inthemeninthe DM group, compared to 33.6±6.4% in the women intheNGTgroup,31.0±6.4%inthewomeninthe IGTgroupand32.0±5.2%inthewomenintheDM group. In both sexes, the serum cholesterol efflux capacitytendedtobelowerinthesubjectswithIGT orDMthaninthosewithNGT,althoughthedifferencewasnotsignificant(P = 0.224formen,P = 0.062 forwomen).Inordertoexaminetheinfluenceofthe presenceofglucoseintolerance,wedividedthestudy subjects into an NGT group and glucose intolerance group.…”
Section: Cholesterol Efflux Assaymentioning
confidence: 99%